

DEC 13 2006

VPI/00-129-1 DIV US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/692,355
Confirmation No.: 8543
Filing Date: October 23, 2003
Examiner: Kahsay Habte, Ph.D.
Group Art Unit: 1624
Applicants: Robert Davies, et al.
For: PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS

Cambridge, Massachusetts
December 13, 2006

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TERMINAL DISCLAIMER UNDER 37 C.F.R. § 1.321(b) and (c)

Dear Sir:

VERTEX PHARMACEUTICALS INCORPORATED, a corporation organized and existing under the laws of the Commonwealth of Massachusetts, having an office and place of business at 130 Waverly Street, Cambridge, Massachusetts 02139-4242 ("VERTEX PHARMACEUTICALS INC."), represents that it is the assignee of record of the entire right, title and interest, by assignment, of the following:

United States patent application Serial No. 10/692,355 (hereinafter "the '355 application"), for "PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS", was filed on September 14, 2001. A related application, Serial No. 10/624,800 (now United States Patent 7,008,943; hereinafter "the '948 patent), was filed March 28, 2002.

An assignment of the entire right, title and interest in and to the subject matter of United States patent application Serial No. 09/952,671, now United States Patent 6,660,731 (the parent of the '948 patent) was recorded in the United States Patent and Trademark Office on August 22, 2003 at Reel/Frame: 013901/0159.

The undersigned, on behalf of VERTEX PHARMACEUTICALS INC., hereby disclaims the terminal portion of any patent granted on the '355 application which would extend beyond the expiration date of the '948 patent.

The undersigned, on behalf of VERTEX PHARMACEUTICALS INC., agrees that any patent so granted on the '355 application shall be enforceable only for and during such period as the legal title to said patent shall be the same as the legal title to the '948 patent, this agreement to run with any patent granted on the '355 application and to be binding upon the grantee of the patent and its successors and assigns.

The undersigned does not disclaim any terminal portion of any patent granted on the '355 application prior to the full statutory term of the '948 patent, in the event that the '948 patent subsequently (a) expires for failure to pay a maintenance fee, (b) is held unenforceable, (c) is found invalid by a court of competent jurisdiction, (d) is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. § 1.321(a), (e) has all claims canceled by a reexamination certificate, or (f) is otherwise terminated prior to expiration of its statutory term, except for the separation of legal title stated above.

The undersigned hereby states and certifies that:

1. The undersigned is an agent of record in the above-identified patent application and is authorized to act on behalf of assignee corporation in connection with said application; and

2. The above-identified assignment document has been reviewed and, to the best of the undersigned's and assignee's knowledge and belief, title to the '948 patent and to the '355 application is in assignee.

Respectfully submitted,


Jennifer G. Che (Reg. No. 58,035)
Agent for Applicants
VERTEX PHARMACEUTICALS INCORPORATED
130 Waverly Street
Cambridge, Massachusetts 02139
Telephone: (517) 444-6525
Facsimile: (617) 444-6483